Review Article
Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
Table 1
Overview of studies included in meta-analysis.
| Study | First author/year | Investigational treatment | Control treatment | Primary endpoint | Number of patients (ITT) (active/control) |
| TML | Bennouna 2012 [9] | Chemotherapy (oxaliplatin or irinotecan based) plus bevacizumab | Chemotherapy (oxaliplatin or irinotecan based) alone | OS | 819 (409/410) | CORRECT | Grothey 2013 [14] | Regorafenib | Placebo | OS | 760 (505/255) | BEBYP | Masi 2013 [10] | Chemotherapy (FOLFIRI, mFOLFOX) plus bevacizumab | Chemotherapy (FOLFIRI, mFOLFOX) alone | PFS | 184 (92/92) | VELOUR subgroup | Allegra 2012 [13] | FOLFIRI plus aflibercept | FOLFIRI | OS | 373 (186/187) | AGITG subgroup | Siu 2013 [16] | Cetuximab plus brivanib | Cetuximab | OS | 310 (152/158) | FOSCO | Hoehler 2013 [17] | FOLFOX/FOLFIRI plus sorafenib | FOLFOX/FOLFIRI plus placebo | PFS | 69 (32/37) | RAISE | Tabernero 2015 [18] | FOLFIRI plus ramucirumab | FOLFIRI plus placebo | PFS | 1072 (536/536) | CONCUR | Li 2015 [15] | Regorafenib | Placebo | OS | 81 |
|
|